MTOR and neoplasm: conducted a study involving 220 HCC patients treated with sorafenib, in which they examined the expression of seven actionable genes (VEGFR2, PDGFR-β, c-Kit, Raf1, EGFR, mTOR, and FGFR1) in tumor tissues compared to those in adjacent normal tissues.